Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 205.00 53,316 16:35:14
Bid Price Offer Price High Price Low Price Open Price
202.00 210.00 206.00 203.50 206.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.04 -20.97 -55.70 65.0
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:14 UT 3,000 205.00 GBX

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Takeover Rumours

Reneuron (RENE) Share Charts

1 Year Reneuron Chart

1 Year Reneuron Chart

1 Month Reneuron Chart

1 Month Reneuron Chart

Intraday Reneuron Chart

Intraday Reneuron Chart

Reneuron (RENE) Discussions and Chat

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:35:14205.003,0006,150.00UT
15:22:24202.401,6683,376.03O
15:15:51208.802,5005,220.00O
14:51:40203.805,00010,190.00O
14:39:38203.88340693.19O
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

DateSubject
25/6/2019
09:20
Reneuron Daily Update: Reneuron Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 205p.
Reneuron Group Plc has a 4 week average price of 202.50p and a 12 week average price of 111.50p.
The 1 year high share price is 332.50p while the 1 year low share price is currently 47p.
There are currently 31,801,617 shares in issue and the average daily traded volume is 159,043 shares. The market capitalisation of Reneuron Group Plc is £65,193,314.85.
19/6/2019
16:22
martinfrench: still dont also understand why he paid around 5p for what was at the time a rene price of about 3p (rough), when he could have surely got a better deal out of rene?
11/6/2019
05:41
dickbush: Woodford's problems clearly impacting RENE's share price IN THE SHORT TERM. Looks like an opportunity to add. The Chairman bought 80,000 at between 220 and 240p.
10/5/2019
09:37
garth: daf, The point is, they sold at 267p, not 400p or 600p. One has to assume that if they thought the share price was going to get there any time soon they would have waited. Now, of course, we all know that even insiders make poor judgments about share price movements. You pays your money, you make your choice. G.
09/5/2019
13:25
dickbush: Influenced by Wall Street, which is again worrying about trade conflict with China, our Market is declining. RENE has had a run from less than 50p to 325p. Until we get some more, hopefully, good news, the share price is there to be shot at. I'm willing to gamble on the news continuing to be good. So, shorters, do your worst. Just remember that news on further deals could come at any time.
05/5/2019
00:56
lauders: Thanks for that lead daffodil4. After a bit of searching I found it: Https://woodfordfunds.com/funds/holdings/reneuron/ The part you quoted in full: Investment case summary The investment case for ReNeuron revolves around a solid understanding of the company’s technology, fostered through a long relationship with the company and bolstered by encouraging developmental progress. Meanwhile, ReNeuron’s strategy of seeking out-licensing agreements for individual programmes at appropriate points in their development, also appears sensible, from the perspective of shareholder value creation and as an effective way of funding the business towards commercialisation. We believe the share price has consistently and profoundly undervalued the future potential of ReNeuron’s technologies and are very excited about the opportunity that lies ahead for the business.
03/5/2019
16:01
manc10: Facts to discuss? What facts? rene doesn’t work to a high enough percentage, so it's useless, hence its share price being lower than it was 5 years ago !! blockbusters are worth £10's billions and take 15 years to come to market. Very true!
16/4/2019
14:53
jensonbensonjohnson: It's speculation, Lauders, yes, but ... After the April 4th efficacy RNS, Michael Hunt said this: "[...] even though the announcement itself is really more of a *teaser* for data we will be formally presenting in conference in Vancouver at the end of this month" [ Said within first 30 seconds here: [...] ] He's always been straight up; for him to have said that is a really strong indicator of good news to come. Directors/insiders have bought substantial numbers of shares at 225p. They've been given incentives directly related to doubling the share price from these levels. They must believe that's realistic. I've been following RENE for 15+ years and I feel it's changed fundamentally now. I feel very confident that the rises we've seen so far are really just the tip of the iceberg.
13/4/2019
04:13
lauders: Https://www.stockopedia.com/articles/reneuron-share-price-hits-a-new-52-week-high-2091/ Making sense of 52 week highs 52 week highs are always good news. But you might be surprised to know that the prices of high performing shares can be slow to move when these companies publish positive earnings news. Studies show it happens because investors are wary about bidding high performing shares any higher (even if they deserve it). This unusual behaviour is down to what the psychologists Amos Tversky and Daniel Kahneman called anchoring-and-adjustment. We form beliefs by using reference points (like share prices). But as new information comes to light (like earnings reports) we're often slow to update our beliefs away from the original anchor point. Evidence shows this tug-of-war usually ends with the ‘new high’ stock actually drifting higher in price over the coming weeks and months. The upward trend is called “post earnings announcement drift”. As the news sinks in, momentum takes over and the price moves higher. A look at Reneuron’s StockReport could offer more insight into what’s driving the momentum in its share price - and whether that might continue. If there is some positive media over the weekend the momentum may continue next week, if not there could be a slight pull back for a few days until people start to "speculate" on the details that could be shared on 26th April: Further read-outs from the patients treated in the Phase 1/2 study will be presented at the 6th Annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada, on 26 April 2019. Information regarding this conference may be found at: Https://www.regonline.com/builder/site/default.aspx?EventID=2548135 Also good to see that RENE are being very active when it comes to conferences/events and will be in Kyoto at this event per the website (link below): Https://www.isev.org/page/ISEV2019 Http://www.reneuron.com/news/events/
10/4/2019
14:58
jensonbensonjohnson: I like the incentive conditions: 1) When the Company has signed out-licensing deal(s) for any of its technologies or programmes which, together with other financial resources, provides sufficient funding to allow the achievement of clinical proof of concept data for the CTX and hRPC programmes, one third of the options will vest. 2) When the Company's share price has doubled from the price at the date of grant, one third of the options will vest. 3) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.
06/3/2019
09:08
pdt: The following was posted on the othet board this morning by Cadburyhill; Summary of research note this morn by Stifel is below. "Our investment thesis on ReNeuron is that the stock is fundamentally mispriced and that the delivery of positive clinical data from either of its two main assets will prompt either 1) a long overdue re-rating in the market or 2) industry partners to step in and ascribe value where the market does not. The recent impressive Phase II results with hRPCs in retinitis pigmentosa (RP) has sparked a ~70% share price gain, but in the context of our 625p TP and >60p net cash/share, scenario 1 may be starting to play out but there is a long way to go yet. Meanwhile, we expect industry partners, that were interested in licensing the hRPC asset last year, will be evaluating the asset more intensely now in light of the data, while recent M&A activity in the retinal (gene therapy) space - Roche's $4.3bn acquisition of Spark Therapeutics and Biogen's $800m purchase of Nightstar Therapeutics - demonstrates the value that industry players are currently placing on novel (retinal) technologies. Yet ReNeuron's retinal cell approach has much broader potential applicability than mutation-specific gene therapy. Scenario 2 may play out before scenario 1 can take hold. Reiterate Buy." It will be disappointing if it is taken out before value is realised. Woodford has the largest holding but he purchased a lot of that at 500p so not sure he would want to exit at this level after waiting so long ??
Reneuron share price data is direct from the London Stock Exchange
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190625 21:45:41